文献速递癫痫

新诊断癫痫患者抗癫痫药物耐受性研究

Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy.
PubMed 文献 · JAMA Neurol · 2020-01-01

该纵向队列研究纳入1982至2012年苏格兰格拉斯哥专科门诊新诊断并治疗的癫痫患者1795例,分析抗癫痫药物不可耐受不良事件的相关因素及时间变化。结果显示,女性、成人、治疗前发作次数多、既往因不良事件停药次数多及合并用药多与不可耐受风险升高相关;尽管第二代抗癫痫药物作为初始单药治疗的比例显著增加,但三个时期的总体不可耐受不良事件率无差异。

要点

  • 女性、成人、治疗前发作>5次及既往因不良事件停药次数多与不可耐受风险升高相关。
  • 第二代抗癫痫药物作为初始单药比例从22.3%增至68.7%,但总体不可耐受率无改善。
  • 临床需关注女性、成人及多次发作患者的不良事件风险,加强耐受性监测。

核心结论

  • 第二代抗癫痫药物使用增加未改善总体治疗耐受性,需在药物开发中更努力提升耐受性。

研究设计与样本

  • 纵向队列研究,纳入1982年7月至2012年10月苏格兰格拉斯哥专科门诊新诊断并治疗的癫痫患者1795例,随访至2016年4月或死亡。

主要发现

  • 3241次抗癫痫药物处方中,504次(15.6%)因不可耐受不良事件在6个月内停药。
  • 与18-64岁成人相比,<18岁儿童不可耐受不良事件率更低(aHR 1.58,95%CI 1.07-2.32);与≥65岁相比,18-64岁成人风险更高(aHR 1.90,95%CI 1.19-3.02)。
  • 女性(aHR 1.60,95%CI 1.30-1.96)和治疗前发作>5次(aHR 1.24,95%CI 1.03-1.49)与不可耐受风险升高相关。
  • 每增加一次因不良事件停药(aHR 1.18,95%CI 1.09-1.28)和每增加一种合并抗癫痫药物(aHR 1.31,95%CI 1.04-1.64),不可耐受风险升高。

临床怎么用

  • 对女性、成人、治疗前发作次数多、既往因不良事件停药次数多及合并用药多的患者,应加强耐受性监测。

局限性

  • 单中心专科门诊队列,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tolerability is a key determinant of the effectiveness of epilepsy treatment. It is important to evaluate whether the overall tolerability has improved. OBJECTIVE: To identify factors associated with poor tolerability of antiseizure medications (ASMs) and examine temporal changes in tolerability. DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal cohort study at a specialist clinic in Glasgow, Scotland. Patients with newly diagnosed and treated epilepsy between July 1982 and October 2012 were included from 2282 eligible individuals. They were followed up until April 2016 or death. Data analysis was completed in August 2019. EXPOSURES: Antiseizure medications. MAIN OUTCOMES AND MEASURES: Univariable and multivariable survival analyses were performed to examine associations between potential risk factors and development of intolerable adverse effects (AEs). Intolerable AE rates of the ASMs as the initial monotherapy were compared between 3 epochs (July 1982-June 1992, July 1992-June 2002, and July 2002-April 2016). RESULTS: Of 1795 patients, 969 (54.0%) were male, and the median (interquartile range) age was 33 (21-50) years. A total of 3241 ASMs were prescribed during the period, of which 504 (15.6%) were discontinued within 6 months owing to intolerable AEs. Children younger than 18 years had lower intolerable AE rates than adults (vs aged 18-64 years: adjusted hazard ratio [aHR], 1.58; 95% CI, 1.07-2.32; vs aged ≥65 years: aHR, 1.90; 95% CI, 1.19-3.02) while female individuals (aHR, 1.60; 95% CI, 1.30-1.96) and those who had more than 5 pretreatment seizures (aHR, 1.24; 95% CI, 1.03-1.49) were associated with having higher risk. For each ASM trial, the risk of intolerable AEs increased with the number of previous drug withdrawals due to AEs (aHR, 1.18; 95% CI, 1.09-1.28) and the number of concomitant ASMs (aHR, 1.31; 95% CI, 1.04-1.64). The proportion of second-generation ASMs prescribed as the initial monotherapy increased from 22.3% (33 of 148) in the first epoch to 68.7% (645 of 939) in the last (P < .001). Although differences in intolerable AE rates and types of AEs were found between the ASMs, there was no difference in the overall intolerable AEs rates to the initial monotherapy across the 3 epochs (first: 10.1% [15 of 148]; second: 13.8% [98 of 708]; third: 14.0% [131 of 939]; P = .41). CONCLUSIONS AND RELEVANCE: In this cohort study, the increased use of the second-generation ASMs had not improved overall treatment tolerability. Greater effort to improve tolerability in ASM development is needed.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Alsfouk BAA, Brodie MJ, Walters M, et al. Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy. JAMA Neurol. 2020. PMID: 32091535. doi:10.1001/jamaneurol.2020.0032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。